Business, energy, technology, markets and global industry news from Business News Today

IB1001-304

PharmaDeviceNews IB1001-304
IntraBio’s pivotal Phase III CACNA1A trial is enrolling patients as levacetylleucine moves into a key clinical test, with recruitment expected to be completed in October 2026. Representative image.
Pharma & Biotech

What IntraBio’s IB1001-304 Phase III trial could reveal about CACNA1A treatment

IntraBio’s Phase III CACNA1A trial is enrolling, with October recruitment completion targeted as levacetylleucine enters a pivotal test.

Read More